Topical selective T-type blockers for the treatment of pruritus
局部选择性 T 型阻滞剂治疗瘙痒
基本信息
- 批准号:9907737
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2021-02-28
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAction PotentialsAcuteAddressAdultAdverse effectsAffectAmericanAnti-inflammatoryAntipruritic EffectAntipruriticsAutoimmune ResponsesBehaviorBlood CirculationC FiberCD4 Positive T LymphocytesCalciumCalcium Channel BlockersCardiotoxicityCellsChemicalsClinical ResearchCytochromesDataDermatologicDermatologyDevelopmentDiseaseDoseEsthesiaExhibitsExperimental Autoimmune EncephalomyelitisFamilyFire - disastersFunctional disorderGoalsHealthHidradenitis SuppurativaHistamineHumanHuman GenomeImmuneImmunologyIn VitroInflammationInflammatoryInvestigational New Drug ApplicationLeadLegal patentLightLiverMechanoreceptorsMediatingMetabolicMetabolismMicrosomesModelingMusNamesNerveNerve EndingsNeuronsNitrogenNociceptionOral AdministrationPatientsPatternPerceptionPeripheralPeripheral Blood Mononuclear CellPermeabilityPharmaceutical ChemistryPharmacologyPhaseProductionPropertyProtein IsoformsPrurigoPruritusResistanceRiskRodentRoleSafetyShapesSkinSmall Business Innovation Research GrantStimulusStructureSymptomsSynapsesT-LymphocyteT-Type Calcium ChannelsTNF geneTherapeuticTimeTopical applicationTouch sensationToxic effectWorkabsorptionanalogassociated symptombasechronic inflammatory skinchronic itchcytokinedesignimprovedin vivoin vivo Modelinhibitor/antagonistkeratinocyte differentiationmacrophagenext generationnovelnovel therapeuticsoff-patentpediatric patientspre-clinicalpreclinical studypublic health relevanceresponseskin disorder
项目摘要
Project Summary / Abstract: Pruritus, also called itch, is the most frequent dermatological symptom in the US
with up to 20% of Americans being affected. Pruritic stimuli are detected by a subset of nociceptive neurons,
pruriceptors, which fire action potential in response to peripheral activation by TH2 or TH17 molecules induced
by chronic inflammatory skin diseases such as ichthyosis, prurigo nodularis, and hidradenitis suppurativa. T-type
calcium channels contribute to the firing behavior of itch-sensing neurons in synaptic skin nerve terminals and
have recently been discovered to mediate calcium entry in immune cells. This T-type calcium channel expression
pattern is consistent with their critical roles at detecting itch sensations associated with skin inflammatory
diseases. Preliminary work has enabled us to formulate the central hypothesis that topical inhibition of the three
T-type channel isoforms in the skin will silence action potential (AP) discharge of itch Aδ and C-fibers induced
by pruritogenic and inflammatory cytokines, will directly reduce the release of these cytokines by TH2 or TH17
cells, and will lead to improved efficacy and limited systemic exposure, together reducing the risk of adverse
effects compared to systemic treatments. Our hypothesis is strongly supported by our experimental findings.
First, our lead compound, DX416, is a potent inhibitor of the three T-type channels, Cav3.1, Cav3.2, and Cav3.3
at sub-micromolar levels. Second, treatment with DX416 does not induce psychoactivity in rodents but
profoundly reduces histamine-evoked itch in mice after intradermal administration. Third, we discovered DX401,
a T-type blocker that reduces histamine-evoked itch after oral administration. Fourth, we show for the first time
that these two Cav3s blockers, DX416 and DX401, significantly reduce the release of TH2 pruritic cytokine, IL-
31, after human peripheral blood mononuclear cell (PBMC) activation, and TH17-synergizing cytokine, TNFα, by
activated macrophages. The overall goal of this collaborative effort between DermaXon’s experts in medicinal
chemistry, immunology, and dermatology is to demonstrate the technical feasibility of developing inhibitors of
skin T-type channels as novel therapeutics for the topical treatment of pruritus associated with inflammatory skin
diseases. Our objectives in this proposal are: Aim 1) complete the optimization of our first topical T-type lead
inhibitor DX416, based on our previously designed chemotypes and characterize their Cav3s activity and
selectivity; Aim 2) compare the effect of four Cav3s blockers selected in SA1 on proinflammatory and
pruritogenic cytokine release by activated immune cells, and assess their safety; Aim 3) compare the anti-pruritic
efficacy after intra-dermal administration of two T-type channels inhibitors selected in Aim 2 using the histamine-
evoked acute itch and the dry skin chronic itch in vivo models. The identification of lead compounds that are
active in preclinical acute and chronic itch models will set the stage for a next generation of topical pruritus
therapeutics to be used in both adult and pediatric patients suffering from itch associated with inflammatory skin
diseases, and will support development of a novel therapeutic topical treatment.
项目概要/摘要:瘙痒,也称为瘙痒,是美国最常见的皮肤病症状
多达20%的美国人受到影响。瘙痒刺激由伤害感受神经元的子集检测,
免疫感受器,其响应于由TH 2或TH 17分子诱导的外周激活而激发动作电位
慢性炎症性皮肤病,如鱼鳞病、结节性湿疹和化脓性汗腺炎。t型
钙通道有助于突触皮肤神经末梢中的痒感神经元的放电行为,
最近发现其介导免疫细胞中的钙进入。这种T型钙通道表达
模式与它们在检测与皮肤炎症相关的瘙痒感觉中的关键作用一致
疾病初步的工作使我们能够制定的中心假设,局部抑制的三个
皮肤中的T型通道亚型将使瘙痒Aδ和C纤维诱导的动作电位(AP)放电沉默
通过促炎性和炎性细胞因子,将直接减少TH 2或TH 17释放这些细胞因子
细胞,并将导致改善的疗效和有限的全身暴露,共同降低不良反应的风险,
与全身性治疗相比。我们的假设得到了实验结果的有力支持。
首先,我们的先导化合物DX 416是三种T型通道Cav3.1、Cav3.2和Cav3.3的有效抑制剂
在亚微摩尔水平上。其次,用DX 416治疗不会诱导啮齿动物的精神活动,
在皮内给药后显著降低小鼠中组胺诱发的瘙痒。第三,我们发现了DX 401,
一种T型阻滞剂,口服后可减少组胺引起的瘙痒。第四,我们首次展示
这两种Cav 3s阻断剂DX 416和DX 401显著减少了TH 2炎性细胞因子IL-1的释放。
31,在人外周血单核细胞(PBMC)活化和TH 17协同细胞因子TNFα后,
激活的巨噬细胞DermaXon的医学专家之间合作的总体目标是
化学,免疫学和皮肤病学的研究是为了证明开发抑制剂的技术可行性。
皮肤T型通道作为局部治疗与炎症性皮肤相关的瘙痒症的新疗法
疾病我们的目标是:目标1)完成我们的第一个局部T型电极导线的优化
抑制剂DX 416,基于我们先前设计的化学型并表征其Cav 3s活性,
选择性;目的2)比较在SA 1中选择的四种Cav 3s阻断剂对促炎性和
通过激活的免疫细胞释放促炎性细胞因子,并评估其安全性;目的3)比较
使用组胺皮内给药目标2中选择的两种T-型通道抑制剂后的功效-
诱发急性瘙痒和干性皮肤慢性瘙痒的体内模型。确定的铅化合物,
在临床前急性和慢性瘙痒模型中的活性将为下一代局部瘙痒奠定基础
用于患有与炎症性皮肤相关的瘙痒的成人和儿童患者的治疗剂
疾病,并将支持一种新的治疗局部治疗的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fanny Astruc Diaz其他文献
Fanny Astruc Diaz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fanny Astruc Diaz', 18)}}的其他基金
Novel therapeutic target to combat cutaneous lupus
对抗皮肤狼疮的新治疗靶点
- 批准号:
10255592 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis
选择性抑制皮肤CYP26A1治疗鱼鳞病
- 批准号:
9255097 - 财政年份:2016
- 资助金额:
$ 22.5万 - 项目类别:
Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis
选择性抑制皮肤CYP26A1治疗鱼鳞病
- 批准号:
9792246 - 财政年份:2016
- 资助金额:
$ 22.5万 - 项目类别:
Inhibition of retinoic acid metabolism for reversal of cognitive deficits in AD
抑制视黄酸代谢以逆转 AD 认知缺陷
- 批准号:
8648292 - 财政年份:2013
- 资助金额:
$ 22.5万 - 项目类别:
相似海外基金
Kilohertz volumetric imaging of neuronal action potentials in awake behaving mice
清醒行为小鼠神经元动作电位的千赫兹体积成像
- 批准号:
10515267 - 财政年份:2022
- 资助金额:
$ 22.5万 - 项目类别:
Signal processing in horizontal cells of the mammalian retina – coding of visual information by calcium and sodium action potentials
哺乳动物视网膜水平细胞的信号处理 â 通过钙和钠动作电位编码视觉信息
- 批准号:
422915148 - 财政年份:2019
- 资助金额:
$ 22.5万 - 项目类别:
Research Grants
CAREER: Resolving action potentials and high-density neural signals from the surface of the brain
职业:解析来自大脑表面的动作电位和高密度神经信号
- 批准号:
1752274 - 财政年份:2018
- 资助金额:
$ 22.5万 - 项目类别:
Continuing Grant
Development of Nanosheet-Based Wireless Probes for Multi-Simultaneous Monitoring of Action Potentials and Neurotransmitters
开发基于纳米片的无线探针,用于同时监测动作电位和神经递质
- 批准号:
18H03539 - 财政年份:2018
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Population Imaging of Action Potentials by Novel Two-Photon Microscopes and Genetically Encoded Voltage Indicators
通过新型双光子显微镜和基因编码电压指示器对动作电位进行群体成像
- 批准号:
9588470 - 财政年份:2018
- 资助金额:
$ 22.5万 - 项目类别:
Enhanced quantitative imaging of compound action potentials in multi-fascicular peripheral nerve with fast neural Electrical Impedance Tomography enabled by 3D multi-plane softening bioelectronics
通过 3D 多平面软化生物电子学实现快速神经电阻抗断层扫描,增强多束周围神经复合动作电位的定量成像
- 批准号:
10009724 - 财政年份:2018
- 资助金额:
$ 22.5万 - 项目类别:
Enhanced quantitative imaging of compound action potentials in multi-fascicular peripheral nerve with fast neural Electrical Impedance Tomography enabled by 3D multi-plane softening bioelectronics
通过 3D 多平面软化生物电子学实现快速神经电阻抗断层扫描,增强多束周围神经复合动作电位的定量成像
- 批准号:
10467225 - 财政年份:2018
- 资助金额:
$ 22.5万 - 项目类别:
Fast high-resolution deep photoacoustic tomography of action potentials in brains
大脑动作电位的快速高分辨率深度光声断层扫描
- 批准号:
9423398 - 财政年份:2017
- 资助金额:
$ 22.5万 - 项目类别:
Noval regulatory mechanisms of axonal action potentials
轴突动作电位的新调节机制
- 批准号:
16K07006 - 财政年份:2016
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
NeuroGrid: a scalable system for large-scale recording of action potentials from the brain surface
NeuroGrid:用于大规模记录大脑表面动作电位的可扩展系统
- 批准号:
9357409 - 财政年份:2016
- 资助金额:
$ 22.5万 - 项目类别: